CPI-1205

N/A

Report date: 2026/02/03 20:00:14
NME

Base Information

Drug NameCPI-1205
Drug Alias NameCPI-1205
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 inhibitors
TargetsHistone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesConstellation Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesConstellation Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A